Swedish Orphan plans SEK 3 billion term loan, €280 million revolver

By Wendy Van Sickle

Columbus, Ohio, Sept. 30 – Swedish Orphan Biovitrum AB (publ) said it plans to get a new SEK 3 billion term loan and a new €280 million revolving credit facility, each with a term of up to five years, to finance a portion of its acquisition of Dova Pharmaceuticals, Inc. by way of a tender offer in a transaction valued at $915 million.

Both new facilities will be arranged by Danske Bank and Skandinaviska Enskilda Banken.

The remaining part of the purchase is planned to be financed through Swedish Orphan Biovitrum’s existing credit facilities.

Swedish Orphan Biovitrum, known as Sobi, is a Stockholm-based specialty health-care company focused on rare diseases.

Dova Pharmaceuticals was founded in 2016 to commercialize Doptelet, a second-generation small-molecule thrombopoietin receptor agonist used in the treatment of thrombocytopenia by increasing platelet count.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.